DIA brings you a symposium with interactive dynamics, where you will engage in discussions with key stakeholders influencing the advancement and implementation of regulatory convergence initiatives in Latin America. Join us to discuss multi-regional cooperation, global harmonization, and best practices related to Latin America’s regulatory landscape.
Sessions will highlight regulatory approaches and good practices to ensure reliance in Latin American and strategic initiatives to improve collaboration and cooperation.We will be translating:

  • English to Spanish and Portuguese
  • Spanish to English and Portuguese
  • Portuguese to English and Spanish

DIA can provide a letter to confirm your onsite participation as long as you have:

  • Already registered for this conference and
  • Paid the registration for this conference

To request a confirmation letter please send an email to Megan Stevens at  Megan.Stevens@diaglobal.org.

Content Preview Webinar

The US FDA Generic Drug Program – The Framework to «Sameness» | January 31 | 11:00AM-12:00PM ET
Gain an overview of the legal framework for how generic drugs can be developed for approval in the United States, and more.
Register today.

Who should attend?

Professionals involved in:

  • Drug regulation
  • Clinical research and development
  • Medical and scientific affairs
  • Quality assurance
  • Research and development
  • Strategic sourcing/planning
  • Regulatory affairs

Learning objectives

At the conclusion of this conference, participants should be able to:

  • Discuss various initiatives related to global regulatory convergence and harmonization and their impact on the access of medicines and future R&D in Latin America
  • Examine various approaches and best practices to ensure regulatory reliance in Latin America

Program Committee

  • Mario AlanisGeneral Director of International Affairs
    Federal Commission for the Protection against Sanitary Risks (COFEPRIS), Mexico
  • Peter BakerInternational Relations Specialist, OIP, OGROP
    FDA, United States
  • Maria Guazzaroni Jacobs, PhDDirector, Quality and Regulatory Policy (QRP)
    Pfizer Inc, United States
  • Maria Cristina Mota Pina, MBADirector, Scientific Regulatory Policy and Intelligence – Latin America
    AbbVie, Inc., United States
  • Jaime Oliveira, DrPH, AHIPHead Regulatory Policy and Intelligence LatAm
    Bayer S.A., Brazil
  • Patrícia Oliviera PereiraHead, Office of International Affairs
    Brazilian Health Surveillance Agency – ANVISA, Brazil
  • Ana Padua, MD, MRCP, MSc, RPhHead, LATAM CMC Regulatory Policy
    Roche, Uruguay
  • Ana Patricia Pineda, MScInternational Regulatory Analyst, OIP, OGROP, OC
    FDA, Mexico
  • Analia PorrasAdvisor
    Pan American Health Organization (PAHO), United States